Company Analysis

Aardvark Therapeutics, Inc. (AARD)

Nasdaq: AARD · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2019
Grade5.1
◀ Past 4.4● Present 5.5▶ Future 5.2
5 est.

Who runs Aardvark Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Lee Tien-Li
Chief Executive Officer. First filing Feb 2025, latest Nov 10, 2026, 4 filings in all.
Officers reporting now
4
of 9 people with a filing in the last fifteen months
Directors reporting now
5
9 people on the record since 2025
Officerssales are open-market, Nov 10, 2025 to Nov 10, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Lee Tien-LiChief Executive OfficerFeb 2025Nov 10, 2026none
Jaiman ManasiChief Medical OfficerFeb 2025Nov 10, 2026none
Sun NelsonSee RemarksFeb 2025Nov 10, 20262 · $400,000
Jones BryanChief Operating OfficerFeb 2025Oct 16, 2025none
Directorssales are open-market, Nov 10, 2025 to Nov 10, 2026
NameRoleFirst filingLatest filingSales, 12 months
Zhang ZhongweidirectorOct 2026Oct 8, 2026none
Baynes Roy D.directorFeb 2025Aug 21, 2026none
Chi JeffreydirectorFeb 2025Aug 21, 2026none
Graf Susan EdirectorFeb 2025Aug 21, 2026none
Tong Victor Edward JrdirectorFeb 2025Aug 21, 2026none
Earlier names on the record8, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton AARD · research, not advice